This perspective on Jubert et al. (beginning on page [1015] in this issue of the journal) discusses the use of microdosing with environmental carcinogens to accelerate the evaluation and optimization of chemopreventive interventions. The need for chemoprevention of environmental carcinogenesis is considered, as are the structure of microdosing, or phase 0, trials, technologies required to conduct microdose studies in this context, and ethical concerns. We also reflect on what microdosing studies have taught us to date.
No takes yet. Share an insight, caveat, or question.
Kensler et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: